ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial

Reuters

2025/11/12

ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial

ProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582887375"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582887375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582887375?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582887375","market":"us","top_or_hot":-1,"title":"ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PMN\">ProMIS Neurosciences Inc</a>. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMN","symbol_name":"ProMIS Neurosciences Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL9tGKFT:1","article_id":"2582887375","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582887375","pubTimestamp":1762949155,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMN":"ProMIS Neurosciences Inc","BK4139":"生物科技"},"translate_title":"ProMIS Neurosciences报告现金状况增加以及阿尔茨海默病试验取得进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PMN":0.9},"content_text":"ProMIS Neurosciences Reports Increased Cash Position and Progress in Alzheimer's Trial\n    \n\nProMIS Neurosciences Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported research and development expenses of $9.8 million for the quarter, an increase from $2.6 million in the same period of 2024, primarily due to expenditures on the PRECISE-AD Phase 1b clinical trial for its lead candidate, PMN310. General and administrative expenses were $2.0 million, compared to $1.9 million in the prior year quarter. The loss from operations was $11.8 million, up from $4.4 million in the third quarter of 2024. ProMIS also provided a clinical update, stating that its Phase 1b trial in Alzheimer's disease is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 nearing completion. PMN310 continues to demonstrate a favorable safety profile. The company remains on track to report 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109714), on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}